Interventional Radiology and More for HCC


Riccardo Lencioni, MD: Interventional radiology is now able to offer a broad spectrum of interventions for patients with hepatocellular carcinoma, ranging from different tools for image-guided ablation with radiofrequency, microwaves, irreversible electroporation, and others. We can offer intraarterial therapy with chemoembolization or radioembolization, and we can combine different options to maximize the effect in individual patients. This is now supported by multiple studies, including randomized controlled trials and meta-analyses, and is part of the routine multidisciplinary management of patients with HCC in the referral centers.

I think 2018 is a special year because finally we understood lessons. We were able to work hard to truly bring more drugs, more agents, with a significant and meaningful effect to doctors treating hepatocellular carcinoma. I see this as the first step in this new chapter and definitely one of the next steps is to understand how to maximize the effect of these drugs by combining agents, for instance TKIs and immune checkpoint inhibitors, or different alternatives. And also, to understand the synergistic effect between interventional locoregional therapy and these novel systemically active agents.

Transcript Edited for Clarity

Related Videos
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Suneel Kamath, MD
Suneel Kamath, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center